title: BCR-ABL fusion regions as a source of multiple leukemia-specific CD8+ T-cell epitopes.
abstract: For immunotherapy of residual disease in patients with Philadelphia-positive leukemias, the BCR-ABL fusion regions are attractive disease-specific T-cell targets. We analyzed these regions for the prevalence of cytotoxic T lymphocyte (CTL) epitopes by an advanced reverse immunology procedure. Seventeen novel BCR-ABL fusion peptides were identified to bind efficiently to the human lymphocyte antigen (HLA)-A68, HLA-B51, HLA-B61 or HLA-Cw4 HLA class I molecules. Comprehensive enzymatic digestion analysis showed that 10 out of the 28 HLA class I binding fusion peptides were efficiently excised after their C-terminus by the proteasome, which is an essential requirement for efficient cell surface expression. Therefore, these peptides are prime vaccine candidates. The other peptides either completely lacked C-terminal liberation or were only inefficiently excised by the proteasome, rendering them inappropriate or less suitable for inclusion in a vaccine. CTL raised against the properly processed HLA-B61 epitope AEALQRPVA from the BCR-ABL e1a2 fusion region, expressed in acute lymphoblastic leukemia (ALL), specifically recognized ALL tumor cells, proving cell surface presentation of this epitope, its applicability for immunotherapy and underlining the accuracy of our epitope identification strategy. Our study provides a reliable basis for the selection of optimal peptides to be included in immunotherapeutic BCR-ABL vaccines against leukemia.
authors.affiliation: Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands. J.H.Kessler@lumc.nl
authors.forename: J H
authors.initials: JH
authors.lastname: Kessler
authors.forename: S A
authors.initials: SA
authors.lastname: Bres-Vloemans
authors.forename: P A
authors.initials: PA
authors.lastname: van Veelen
authors.forename: A
authors.initials: A
authors.lastname: de Ru
authors.forename: I J G
authors.initials: IJ
authors.lastname: Huijbers
authors.forename: M
authors.initials: M
authors.lastname: Camps
authors.forename: A
authors.initials: A
authors.lastname: Mulder
authors.forename: R
authors.initials: R
authors.lastname: Offringa
authors.forename: J W
authors.initials: JW
authors.lastname: Drijfhout
authors.forename: O C
authors.initials: OC
authors.lastname: Leeksma
authors.forename: F
authors.initials: F
authors.lastname: Ossendorp
authors.forename: C J M
authors.initials: CJ
authors.lastname: Melief
mesh_terms: D000595:Amino Acid Sequence; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology*; D019496:Cancer Vaccines / Q000276:immunology*; D045744:Cell Line, Tumor; D018604:Epitope Mapping / Q000379:methods; D018984:Epitopes, T-Lymphocyte / Q000276:immunology*; D016044:Fusion Proteins, bcr-abl / Q000235:genetics / Q000276:immunology* / Q000378:metabolism; D015234:HLA-A Antigens / Q000276:immunology / Q000378:metabolism; D015789:HLA-A2 Antigen; D015235:HLA-B Antigens / Q000276:immunology / Q000378:metabolism; D059949:HLA-B51 Antigen; D015236:HLA-C Antigens / Q000276:immunology / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000276:immunology* / Q000628:therapy; D008969:Molecular Sequence Data; D010446:Peptide Fragments / Q000235:genetics / Q000276:immunology / Q000378:metabolism; D011485:Protein Binding / Q000276:immunology
chemical_list: D019496:Cancer Vaccines; D018984:Epitopes, T-Lymphocyte; D015234:HLA-A Antigens; C435939:HLA-A*02:01 antigen; C053029:HLA-A*68 antigen; D015789:HLA-A2 Antigen; D015235:HLA-B Antigens; D059949:HLA-B51 Antigen; C079077:HLA-B61 antigen; D015236:HLA-C Antigens; C039966:HLA-C*04 antigen; D010446:Peptide Fragments; D016044:Fusion Proteins, bcr-abl